A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

NCT04300114 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

5

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor R \& D Strategy Adjustment

Conditions

Metastatic Pancreatic Cancer

Interventions

DRUG: Fluzoparib
DRUG: Placebo

Sponsor

Jiangsu HengRui Medicine Co., Ltd.